| Project/Area Number |
21592048
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANAYAMA Hiro-omi 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 教授 (10214446)
MASAYUKI Takahashi 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 講師 (50325255)
NAKATSUJI Hiroyoshi 徳島大学, 病院, 助教 (50437638)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 前立腺癌 / ガレクチンー3 / ホルモン不応性 / ホルモン受容体 / 遺伝子治療 / ガレクチン-3 |
|---|
| Research Abstract |
Galectin-3, has been strongly expressed in hormone-refractory prostate cancer, showed a negative correlation between expression of androgen receptor and galectin-3 in hormone-refractory prostate cancer cell line PC3. Galectin-3 was involved in resistance to apoptosis induced by platinum-based drug and radio therapy through the suppression of the caspase-3 activity and stability of the mitochondria. Galectin-3 is a target protein involved in the resistance of hormone therapy, chemotherapy and radiotherapy in hormone-refractory prostate cancer.
|
